1. Home
  2. COE vs BWAY Comparison

COE vs BWAY Comparison

Compare COE & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

COE

51Talk Online Education Group

HOLD

Current Price

$41.36

Market Cap

271.9M

Sector

Real Estate

ML Signal

HOLD

Logo BrainsWay Ltd.

BWAY

BrainsWay Ltd.

HOLD

Current Price

$17.41

Market Cap

280.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COE
BWAY
Founded
2011
2003
Country
Singapore
Israel
Employees
N/A
N/A
Industry
Other Consumer Services
Medical/Dental Instruments
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
271.9M
280.7M
IPO Year
2016
2019

Fundamental Metrics

Financial Performance
Metric
COE
BWAY
Price
$41.36
$17.41
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$20.50
AVG Volume (30 Days)
2.8K
73.6K
Earning Date
12-05-2025
11-11-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
213.09
EPS
N/A
0.13
Revenue
$68,928,000.00
$49,094,000.00
Revenue This Year
N/A
$335.63
Revenue Next Year
N/A
$22.10
P/E Ratio
N/A
$49.96
Revenue Growth
93.05
27.08
52 Week Low
$12.98
$7.84
52 Week High
$56.13
$17.92

Technical Indicators

Market Signals
Indicator
COE
BWAY
Relative Strength Index (RSI) 36.73 64.84
Support Level $41.33 $14.60
Resistance Level $42.95 $15.56
Average True Range (ATR) 1.06 0.88
MACD -0.56 0.13
Stochastic Oscillator 25.75 99.40

Price Performance

Historical Comparison
COE
BWAY

About COE 51Talk Online Education Group

51 Talk Online Education Group is an online education platform in China, with core expertise in English education. The company's mission is to make quality education accessible and affordable. It's online and mobile education platforms enable students across China to take live interactive English lessons with overseas foreign teachers, on demand. The Group operates in seven principal geographical area: China, Hong Kong, Philippines, Singapore, Malaysia, Thailand and Saudi Arabia.

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Share on Social Networks: